Clinical Trial

Mustang Bio Receives Positive Listing Determination from Nasdaq

WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…

2 months ago

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Company accelerated commercialization with significant new partnerships both in the U.S. and EuropeATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys…

2 months ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials,…

2 months ago

Yunu Welcomes Veteran Life Sciences Commercial Leader Patrick McNamara

McNamara's extensive experience in scaling imaging and eClinical companies through organic growth and acquisition strategies brings a wealth of expertise…

2 months ago

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

Conference call will be held today, Tuesday, November 12 at 9:00 am ETCARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) --…

2 months ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025INDIANAPOLIS and FLORHAM PARK, N.J.,…

2 months ago

Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)  

MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today…

2 months ago

Lifeward Ltd. Reports Third Quarter 2024 Financial Results

Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for…

2 months ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the…

2 months ago